

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: December 17, 2009
Electronic Signature for Cristin Howley Cowles, Ph.D.: /Cristin Howley Cowles/

Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

| | | | |
|---|---|-------------------------------|------------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 10/622,932-Conf. #3572 |
| | | Filing Date | July 18, 2003 |
| | | First Named Inventor | Subhashis Banerjee |
| | | Art Unit | 1643 |
| | | Examiner Name | David J. Blanchard |
| Sheet | 1 | of | 4 |
| | | Attorney Docket Number | 117813-18705 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|----------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. | Document Number Number:Kind Code ² (# known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | A1* | 5,958,953 | 07-07-1998 | Marfat et al. | |
| | A2* | 6,537,549 | 03-25-2003 | Tobinick | |
| | A3* | 6,090,382 | 07-18-2000 | Salfeld et al. | |
| | A4* | 6,258,562 | 07-10-2001 | Salfeld et al. | |
| | A5* | 6,569,619 | 01-21-2005 | Salfeld et al. | |
| | A6* | 7,588,761 | 09-15-2009 | Salfeld et al. | |
| | A7* | US 2003-0219438 A1 | 11-27-2003 | Salfeld et al. | |
| | A8* | US 2009-0155205 A1 | 06-18-2009 | Salfeld et al. | |
| | A9* | US 2004-0033228 A1 | 02-19-2004 | Krause et al. | |
| | A10* | US 2003-0206898 A1 | 11-06-2003 | Fischkoff et al. | |
| | A11* | US 2009-0110679 A1 | 04-30-2009 | Li et al. | |
| | A12* | US 2009-0017472 A1 | 01-15-2009 | Stuhlmüller et al. | |
| | A13* | US 2009-0258018 A1 | 10-15-2009 | Medich et al. | |
| | A14* | US 2009-0239259 A1 | 09-24-2009 | Hsieh et al. | |
| | A15* | US 2009-0226530 A1 | 09-10-2009 | Lassner et al. | |
| | A16* | US 2009-0271164 A1 | 10-29-2009 | Peng et al. | |
| | A17* | US 2004-0126372 A1 | 07-01-2004 | Banerjee et al. | |
| | A18* | US 2004-0131614 A1 | 07-08-2004 | Banerjee et al. | |
| | A19* | US 2004-0126373 A1 | 07-01-2004 | Banerjee et al. | |
| | A20* | US 2004-0151722 A1 | 08-05-2004 | Banerjee et al. | |
| | A21* | US 2008-0193466 A1 | 08-14-2008 | Banerjee et al. | |
| | A22* | US 2004-0136990 A1 | 07-15-2004 | Banerjee et al. | |
| | A23* | US 2004-0219142 A1 | 11-04-2004 | Banerjee et al. | |
| | A24* | US 2004-0136989 A1 | 07-15-2004 | Banerjee et al. | |
| | A25* | US 2003-0012786 A1 | 01-16-2003 | Teoh et al. | |
| | A26 | US 2003-0161828 A1 | 08-28-2003 | Abdelghany et al. | |
| | A27 | 7,223,394 | 05-29-2007 | Salfeld et al. | |
| | A28 | 7,541,031 | 06-02-2009 | Salfeld et al. | |
| | A29 | US 2003-0235585 A1 | 12-25-2003 | Fischkoff et al. | |
| | A30 | US 2006-0153846 A1 | 07-13-2006 | Krause et al. | |
| | A31 | US 2004-0009172 A1 | 01-15-2004 | Fischkoff et al. | |
| | A32 | US 2004-0166111 A1 | 08-26-2004 | Kaymakçalan et al. | |
| | A33 | US 2006-0009385 A1 | 01-12-2006 | Hoffman et al. | |
| | A34 | US 2009-0304682 A1 | 12-10-2009 | Hoffman et al. | |
| | A35 | US 2006-0083741 A1 | 04-20-2006 | Hoffman et al. | |
| | A36 | US 2007-0041905 A1 | 02-22-2007 | Hoffman et al. | |
| | A37 | US 2007-0081996 A1 | 04-12-2007 | Hoffman et al. | |
| | A38 | US 2007-0071747 A1 | 03-29-2007 | Hoffman et al. | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO. Those application(s) which are marked with a single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IPW. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B./

Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

| | | | | | |
|---|---|----|-----------------------------|-------------------------------|--------------|
| Substitute for form 1449/PTO | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Application Number | 10/622,932-Conf. #3572 | |
| | | | Filing Date | July 18, 2003 | |
| | | | First Named Inventor | Subhashis Banerjee | |
| | | | Art Unit | 1643 | |
| | | | Examiner Name | David J. Blanchard | |
| Sheet | 2 | of | 4 | Attorney Docket Number | 117813-18705 |

| | | | | |
|-----|--------------------|------------|--------------------|--|
| A39 | US 2007-0172897 A1 | 07-26-2007 | Maksymowych et al. | |
| A40 | US 2007-0292442 A1 | 12-20-2007 | Wan et al. | |
| A41 | US 2008-0166348 A1 | 07-10-2008 | Kupper et al. | |
| A42 | US 2009-0028794 A1 | 01-29-2009 | Medich et al. | |
| A43 | US 2008-0118496 A1 | 05-22-2008 | Medich et al. | |
| A44 | US 2009-0123378 A1 | 05-14-2009 | Wong et al. | |
| A45 | US 2008-0131374 A1 | 06-05-2008 | Medich et al. | |
| A46 | US 2008-0311043 A1 | 12-18-2008 | Hoffman et al. | |
| A47 | US 2008-0227136 A1 | 09-18-2008 | Pla et al. | |
| A48 | US 2007-0202104 A1 | 08-30-2007 | Banerjee et al. | |
| A49 | US 2004-0136991 A1 | 07-08-2004 | Banerjee et al. | |
| A50 | 5,656,272 | 08-12-1997 | Le et al. | |
| A51 | 6,177,077 | 01-23-2001 | Tobinick | |
| A52 | 6,448,380 | 08-30-2001 | Rathjen | |
| A53 | 6,451,983 | 08-30-2001 | Rathjen | |
| A54 | 6,498,237 | 09-20-2001 | Rathjen | |
| A55 | 6,593,458 | 07-15-2003 | Rathjen | |
| A56 | 7,070,775 | 07-31-2003 | Le et al. | |
| A57 | 7,192,584 | 02-21-2002 | Le et al. | |
| A58 | 7,276,239 | 06-29-2006 | Le et al. | |

| | | | |
|---------------------------|--|------------------------|--|
| Examiner Signature | | Date Considered | |
|---------------------------|--|------------------------|--|

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicants' unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B./

Used in Lieu of PTO/SB/08/B
(Based on PTO 01-08 version)

| | | | | | |
|---|---|----|-----------------------------|-------------------------------|--------------|
| Substitute for form 1449/PTO | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Application Number | 10/622,932-Conf. #3572 | |
| | | | Filing Date | July 18, 2003 | |
| | | | First Named Inventor | Subhashis Banerjee | |
| | | | Art Unit | 1643 | |
| | | | Examiner Name | David J. Blanchard | |
| Sheet | 3 | of | 4 | Attorney Docket Number | 117813-18705 |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|---|-----------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Country Code ² -Number-Kind Code ³ (If Known) | | | |
| | B1 | WO 97/29131 | 06-14-1997 | BASF Aktiengesellschaft | |
| | B2 | WO 98/22460 | 05-28-1998 | Darwin Discovery Ltd. | |
| | B3 | WO 02/12502 | 08-07-2001 | Centocor, Inc. | |
| | B4 | JP2001302542 | 10-31-2001 | Tenabe Selyaku Co. | (English abstract only) |
| | B5 | JP11127882 | 05-18-1999 | Nippon Kayaku KK | (English abstract only) |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|---|--|--|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | | |
| | | | | | |
| | C1 | Baugh, John A. et al., "Mechanisms for modulating TNF α in immune and inflammatory disease," <i>Current Opinion in Drug Discovery & Development</i> , Vol. 4(5):635-650 (2001) | | | |
| | C2 | Bodmer, Mark et al., "Preclinical review of anti-tumor necrosis factor monoclonal antibodies," <i>Critical Care Medicine</i> , Vol. 21(10):S441-S446 (1993) | | | |
| | C3 | Elewski "Infliximab for the treatment of severe pustular psoriasis." <i>J. Am. Acad. Dermatol.</i> 2002 Nov;47(5):796-7 | | | |
| | C4 | Grom, Alexei A. et al., "Patterns of Expression of Tumor Necrosis Factor α , Tumor Necrosis Factor, and Their Receptors in Synovia of Patients with Juvenile Rheumatoid Arthritis and Juvenile Spondylarthropathy," <i>Arthritis & Rheumatism</i> , Vol. 39(10):1703-1710 (1996) | | | |
| | C5 | Iyer et al. "Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy." <i>Br. J. Dermatol.</i> 2002 Jan;146(1):118-21 | | | |
| | C6 | Kamarashev et al. "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept." <i>Dermatology.</i> 2002;205(2):213-6 | | | |
| | C7 | Kietz et al., "Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis." <i>Journal of Rheumatology</i> , 28(2):360-362, February 2001. | | | |
| | C8 | Kirby et al. "Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate." <i>Clin. Exp. Dermatol.</i> 2001 Jan;26(1):27-9 | | | |

| | | | |
|---------------------------|--|------------------------|--|
| Examiner Signature | | Date Considered | |
|---------------------------|--|------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO. Those application(s) which are marked with a single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IPW. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B./

Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

| | | | | | |
|---|---|----|---|-------------------------------|------------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/622,932-Conf. #3572 |
| | | | | Filing Date | July 18, 2003 |
| | | | | First Named Inventor | Subhashis Banerjee |
| | | | | Art Unit | 1643 |
| | | | | Examiner Name | David J. Blanchard |
| Sheet | 4 | of | 4 | Attorney Docket Number | 117813-18705 |

| | | |
|-----|--|--|
| C9 | Mang <i>et al.</i> "Response of severe psoriasis to infliximab." <i>Dermatology</i> . 2002;204(2):156-7 | |
| C10 | Mease <i>et al.</i> "Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial." <i>Lancet</i> . 2000 Jul 29;356(9227):385-90 | |
| C11 | Newland <i>et al.</i> "Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type." <i>Int. J. Dermatol.</i> 2002 Jul;41(7):449-52 | |
| C12 | O'Quinn <i>et al.</i> "The effectiveness of tumor necrosis factor α antibody (infliximab) in treating recalcitrant psoriasis: A report of 2 cases." <i>Arch. Dermatol.</i> 2002 May;138(5):644-8. | |
| C13 | Russell-Jones <i>et al.</i> "High-dose interferon and the U.K. guidelines for cutaneous melanoma." <i>Br. J. Dermatol.</i> 2002 Oct;147(4):832-4 | |
| C14 | Schopf <i>et al.</i> "Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α , infliximab." <i>J. Am. Acad. Dermatol.</i> 2002 Jun;46(6):886-91 | |
| C15 | Takematsu, H.: "Absence of tumor necrosis factor- α in suction blister fluids and stratum corneum from patients with psoriasis." <i>Arch Dermatol Res.</i> 1989;281(6):398-400. | |
| C16 | Asadullah, K. <i>et al.</i> "A high prevalence of cytomegalovirus antigenaemia in patients with moderate to severe chronic plaque psoriasis: an association with systemic tumor necrosis factor α overexpression." <i>Br. J. Dermatol.</i> 1999 141(1):94-102 | |
| C17 | Chaudhari, U. <i>et al.</i> "Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial." <i>Lancet</i> 2001 357(9271):1842-7. | |
| C18 | Marks, JD <i>et al.</i> "By-Passing Immunization: Building High Affinity Human Antibodies By Chain Shuffling." <i>Nature Biotechnology</i> 1992 10:779-783. | |
| C19 | Cavagna, L. <i>et al.</i> "Infliximab in the treatment of adult Still's disease refractory to conventional therapy." <i>Clin Exp Rheumatol</i> 2001 19(3):329-332. | |
| C20 | Kraetsch, H. <i>et al.</i> "Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences." <i>Ann Rheum Dis</i> 2001 60(Suppl. 3):iii55-iii57 | |
| C21 | Baeten, D. <i>et al.</i> "Immunomodulatory Effects of Anti-Tumor Necrosis Factor α Therapy on Synovium in Spondylarthropathy." <i>Arthritis & Rheumatism</i> 2001 44(1):186-195 | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /David Blanchard/ | Date Considered | 04/09/2010 |
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO. Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. * Applicants unique citation designation number (optional). * See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B./